Thiosulfuric Acid

Thiosulfuric Acid

SCHEMBL3700745

O=S(=O)(O)S.[NaH].[SnH4]

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022036259-A1 PERSONAL ANTIMICROBIAL CARRIER PAC X, LLC (US) 2022-02-17 WO disclosed
US-20220047050-A1 PERSONAL ANTIMICROBIAL CARRIER PAC X, LLC 2022-02-17 US disclosed
US-9480260-B2 Acrylic polymers containing metallic nanoparticles THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2016-11-01 US disclosed
US-20140288171-A1 ACRYLIC POLYMERS CONTAINING METALLIC NANOPARTICLES THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2014-09-25 US disclosed
US-8779023-B2 In situ formation of nanoparticles in resins THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2014-07-15 US disclosed
US-20110306699-A1 IN SITU FORMATION OF NANOPARTICLES IN RESINS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2011-12-15 US disclosed
WO-2010077985-A1 IN SITU FORMATION OF NANOPARTICLES IN RESINS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2010-07-08 WO disclosed
EP-1567101-A4 PROPHYLACTIC TREATMENT METHODS NUCRYST PHARM CORP (CA) 2009-06-03 EP disclosed
EP-2043611-A2 METAL-CONTAINING FORMULATIONS AND METHODS OF USE Nucryst Pharmaceuticals Corp. (CA) 2009-04-08 EP disclosed
US-7427416-B2 Methods of treating conditions using metal-containing materials NUCRYST PHARMACEUTICALS CORP. (CA) 2008-09-23 US disclosed
EP-1575552-A2 METAL-CONTAINING MATERIALS, COMPOSITIONS AND METHODS Nucryst Pharmaceuticals Corp. (CA) 2005-09-21 EP disclosed
EP-1567101-A2 PROPHYLACTIC TREATMENT METHODS NUCFRYST PHARMACEUTICALS CORP. (CA) 2005-08-31 EP disclosed
WO-2005074949-A1 TREATMENT OF UNGUAL AND SUBUNGUAL DISEASES WITH ANTIMICROBIAL METAL COMPOSITIONS NUCRYST PHARMACEUTICALS CORP. (CA) 2005-08-18 WO disclosed
US-20040191329-A1 Compositions and methods of metal-containing materials NUCRYST PHARMACEUTICALS CORP. (CA) 2004-09-30 US disclosed
US-20040176312-A1 Treatment of ungual and subungual diseases NUCRYST PHARMACEUTICALS CORP. (CA) 2004-09-09 US disclosed
US-20040131698-A1 Methods of treating conditions using metal-containing materials NUCRYST PHARMACEUTICALS CORP. (CA) 2004-07-08 US disclosed
US-20040129112-A1 Metal-containing materials NUCRYST PHARMACEUTICALS CORP. (CA) 2004-07-08 US disclosed
US-20040110738-A1 Prophylactic treatment methods NUCRYST PHARMACEUTICALS CORP. (CA) 2004-06-10 US disclosed
WO-2004037187-A2 METAL-CONTAINING MATERIALS, COMPOSITIONS AND METHODS NUCRYST PHARMACEUTICALS CORP. (CA) 2004-05-06 WO disclosed
WO-2004037186-A2 PROPHYLACTIC TREATMENT METHODS NUCRYST PHARMACEUTICALS CORP. (CA) 2004-05-06 WO disclosed